Prabotulinumtoxin A biosimilar by AEON Biopharma for Spasmodic Torticollis (Cervical Dystonia): Likelihood of Approval

Brought to you by GlobalData

Prabotulinumtoxin A biosimilar is under clinical development by AEON Biopharma and currently in Phase II for Spasmodic Torticollis (Cervical Dystonia). According to GlobalData, Phase II drugs for Spasmodic Torticollis (Cervical Dystonia) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Prabotulinumtoxin A biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Prabotulinumtoxin A biosimilar overview

Prabotulinumtoxin A (Nabota) is a biosimilar of clostridium botulinum A toxin. It is a protein produced by the bacterium Clostridium botulinum. It is formulated as injection powder solution for intradermal and intramuscular route of administration. Nabota is indicated for muscle spasticity, and blepharospasm (eyelid spasms).

It is under development for the treatment of blepharospasm, sleep bruxism, gastroparesis and spasmodic torticollis (cervical dystonia), unspecified musculoskeletal disorders (benign masseteric hypertrophy), cervical dystonia and as preventive treatment of episodic, chronic migraine and post-traumatic stress disorder (PTSD). The drug candidate is an injectable 900 kDa purified botulinum toxin type A complex. It is administered through intramuscular and intradermal routes as a powder for solution.

AEON Biopharma overview

AEON Biopharma, formerly Alphaeon Corp, is a biopharmaceutical company that develops drugs for debilitating medical conditions. It is headquartered in Newport Beach, California, the US.

For a complete picture of Prabotulinumtoxin A biosimilar’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.

More Relevant

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close